This week we would like to present a group of 5 emerging technology startups in medical diagnostics. We think their disruptive technology is definitely worth following. Let us know your thoughts.
BioSentinel is committed to the research and development of tests for Botulinum Neurotoxin. This research has yielded a new kind of testing that is quicker, more accurate, and more sensitive than current tests for Botulinum Neurotoxin. BioSentinel has developed a wide variety of products for testing every class of Botulinum Neurotoxin, and doing so flexibly.
Eutropics technology provides patient-specific tumor susceptibility information to guide treatment of hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). Our proprietary platform provides important insight into an individual patient’s cancer, making personalized medicine a reality. Our technology also provides an important biomarker to guide cancer drug development.
A licensee of UCLA, this company is dedicated to improving patient healthcare using smartphones and biophotonics. Holomic’s first product is a suite of rapid diagnostic test readers for advancing diagnostic accuracy and access. Other products in development include a lens free holographic microscope and handheld analyzers for blood count, allergens, and mercury contamination.
LeukoDx is developing compact table-top POC (point of care) flowcytometer instruments based on microfluidics technology developed at CalTech. They are disposable, single use, test-specific cartridges to be read by NASA’s POC instruments. This is creating a revolutionary breakthrough by which state-of-the-art lab level cell based analysis can be made available 24/7 and brought to the Point-of-Care.
SeqLL specializes in Transcriptome, DNA, and RNA sequencing services using sequencers that are accurate, consistent, and unbiased using small sample quantities. Using Helicos Single Molecule Sequencing, SeqLL was able to discover and analyze gene expression for drug targets, companion diagnostics, and validation. Small RNA measurements give the ability to produce extremely accurate results, giving more valuable data than with other RNA sequencing platforms.
Inside seed, industry subscribers aren’t limited to a blurb and a website link. In about a 3-minute read, subscribers get a compact, non-confidential summary. Not only is it very informative and way more efficient than visiting or scraping websites, but it also lets users reach out to each potential partners if they want to go further. Using secure messaging, seed goes on to provide online deal process tools – from NDA negotiation to data room access. There are no intermediaries and no transaction fees.
is free for scientific research organizations, incubators, and young companies, and available at a fixed rate subscription for corporate use.